Trial Profile

A Phase 1a/b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C137, an Antibody-Drug Conjugate Targeting FGFR2b, in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Antineoplastics (Primary) ; Antineoplastics (Primary) ; BG C 137 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors BeOne Medicines

30 Oct 2025 Number of treatment arms are increased from 2 to 3 by the addition of "Experimental: Phase 1a: Combination Therapy Dose Confirmation and Safety Expansion" arm. Primary end-point "Phase 1a: Recommended Dose(s) for Expansion (RDFE[s])" and inclusion criteria are accordingly modified to add combination therapy.
30 Oct 2025 Planned number of patients changed from 68 to 168.
27 Feb 2025 According to BeiGene media release, data readout is anticipated in first half of 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com